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Introduction: Chronic musculoskeletal pain (CMP) is a very common symptom in patients
with chronic kidney disease (CKD), and is associated with a signiﬁcant deterioration in
quality of life.
Aims: To determine the prevalence and clinical characteristics associated with CMP in
patients with advanced CKD not on dialysis, and to analyse their relation with other uraemic
symptoms and their prognosis signiﬁcance.
Materials and methods: Cross-sectional study to analyse the uraemic symptoms of an unse-
lected cohort of patients with CKD stage 4–5 pre-dialysis. In order to characterise patients
with CMP, demographic and anthropometric data were collected, as well as data on comor-
bidities and kidney function. In addition, inﬂammatory parameters, uric parameters, bone
mineral metabolism including 25-hydroxycholecalciferol (25-OHCC), creatine kinase and
drugs  of potential interest including allopurinol, statins and erythropoiesis-stimulating
agents were recorded.
Results: The study group consisted of 1169 patients (mean age 65 ± 15 years, 54% male). A
total  of 38% of patients complained of CMP, and this symptom was more prevalent in women
than in men (49 vs. 28%; P < .0001). Muscle weakness, pruritus, muscle cramps, ecchymo-
sis,  insomnia, oedema and dyspnoea were the most common symptoms associated with
CMP. There were no signiﬁcant associations between serum levels of creatine kinase, 25-
OHCC, treatment with allopurinol, statins or erythropoiesis-stimulating agents and CMP.
The female gender, elderly age, obesity, comorbidity (mainly diabetes, heart failure or COPD),
and  elevated levels of inﬂammatory markers (C-reactive protein and non-neutrophilic
leukocytes) were the best determinants of CMP.While patients with CMP showed a worse survival rate, a multivariate analysis adjusted
a ruled out the independent association of CMP  with mortality.for demographic datConclusions: CMP is highly prevalent in patients with advanced CKD and is associated with
other common symptoms of chronic uraemia. As with the general population, elderly age,
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the female gender, obesity and some comorbid conditions are the best determinants of
CMP. Increased inﬂammatory markers commonly observed in patients with CMP may have
a  relevant role in its pathogenesis.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Dolor  músculo-esquelético  en  pacientes  con  enfermedad  renal  crónica
Palabras clave:
Enfermedad renal crónica
Dolor músculo-esquelético
Inﬂamación
Síntomas urémicos
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Introducción: El dolor músculo-esquelético crónico (DMEC) es un síntoma muy frecuente en
pacientes con enfermedad renal crónica (ERC), y contribuye de forma importante al deterioro
de  la calidad de vida.
Objetivos: Determinar la prevalencia y características clínicas asociadas al DMEC en
pacientes con ERC avanzada no en diálisis, analizar su relación con otros síntomas urémicos
y  su signiﬁcado pronóstico.
Material y métodos: Estudio transversal en el que se analizó la sintomatología urémica de
pacientes no seleccionados remitidos por ERC estadio 4 y 5 prediálisis. Para caracterizar
aquellos que presentaban DMEC, además de los datos demográﬁcos, antropométricos, la
comorbilidad y la función renal, también se recogieron parámetros de inﬂamación, ácido
úrico, metabolismo óseo-mineral incluyendo 25-hidroxi-colecalciferol (25-OHCC), creatinci-
nasa, y fármacos de potencial interés como alopurinol, estatinas y agentes estimulantes de
eritropoyetina.
Resultados: Se incluyó a 1.169 pacientes con edad media de 65 ± 15 an˜os; el 54% eran hom-
bres.  Un 38% de los pacientes refería DMEC, y este síntoma fue más frecuente en mujeres
que en hombres (49 vs. 28%; p < 0,0001). La debilidad muscular, prurito, calambres, equimo-
sis, insomnio, edemas y disnea fueron los síntomas más frecuentemente asociados al
DMEC. No se observaron asociaciones signiﬁcativas entre niveles de creatincinasa, 25-OHCC,
tratamiento con alopurinol, estatinas o agentes estimulantes de eritropoyetina con DMEC.
Los mejores determinantes de DMEC fueron: mujer, mayor, obesa, con comorbilidad (sobre
todo  diabetes, insuﬁciencia cardiaca o EPOC), y marcadores de inﬂamación elevados (pro-
teína C reactiva y leucocitos no neutróﬁlos).
Aunque los pacientes con DMEC tenían una peor supervivencia, un análisis multivariante
con ajuste simple a datos demográﬁcos descartó que el DMEC fuera un determinante inde-
pendiente de la mortalidad.
Conclusiones: El DMEC es muy prevalente en pacientes con ERC avanzada, y se asocia con
otros síntomas comunes de la uraemia crónica. Al igual que en la población general,
características como sexo femenino, edad avanzada, obesidad y comorbilidad están más
frecuentemente asociados al DMEC. La elevación de los marcadores de inﬂamación asociada
al  DMEC podría ser un hallazgo relevante para explicar su patogenia.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
The symptoms of chronic kidney disease (CKD) are non-
speciﬁc and very variable. Chronic musculoskeletal pain (CMP)
is a very common symptom in CKD1,2 and has a signiﬁcant
effect on the perception of health and quality of life of patients
who  suffer from it.3,4
Previous studies have shown that, despite the high preva-
lence of CMP,  it is very often undervalued and is usually
attributed to different processes, related or not to chronic
uraemia, such as bone and mineral disorders, neuritis, or
inﬂammatory or degenerative osteoarthritis.4–7by-nc-nd/4.0/).
The CMP in CKD is often associated with other symptoms
attributable to uraemia, such as insomnia and fatigue,1–3 or
to psychiatric disorders such as anxiety or depression.8 These
patients need to take large doses of painkillers which, with the
altered drug metabolism associated with uraemia, increases
the risk of adverse reactions.9,10
Despite the importance of CMP in CKD, very few studies
have analysed the clinical characteristics and determining fac-
tors. A better understanding of the origin and characteristics
of the pain could help us to design more  speciﬁc and effective
treatment strategies.
The aims of this study were to determine the preva-
lence of CMP in patients with advanced CKD (ACKD) and to
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nalyse associations with clinical and biochemical parame-
ers, the potential relationship with drugs and the effect on
urvival.
aterials  and  methods
his cross-sectional, observational study included incident
atients referred to the ACKD clinic from January 2000 to
ovember 2014. They were all aged over 18 and had a glomeru-
ar ﬁltration rate of less than 30 ml/min/1.73 m2. No patients
ere excluded.
As part of the clinical interview, which was conducted
y a nephrologist in all cases, information on the presence
f uraemia-associated symptoms was obtained by taking
 speciﬁcally focused patient history, as occurs with all
atients in our ACKD clinic according to protocol. The
ymptoms included were: anorexia; nausea or vomiting;
edema; dyspnoea; decreased physical exercise; fatigue (mus-
le weakness); pruritus; ecchymosis or epistaxis; cramps; cold
ntolerance; night-time insomnia; daytime drowsiness; rest-
ess legs; myoclonus; and CMP.
CMP  was deﬁned as the presence of muscle or bone pain
n any location (upper or lower limbs or trunk) for more  than
hree months, not attributable to trauma, and requiring anal-
esic therapy at least three times a week. The intensity of the
MP  was not collected as data for the study.
Cramp was deﬁned as involuntary, sustained and painful
ontraction of muscles or muscle groups in the lower or
pper limbs, which occurred spontaneously and essentially at
est.
To characterise patients with or without pain, in addition
o demographic data and body mass index, the following were
ncluded as variables of potential interest: the Davies comor-
idity index; haemoglobin; total leucocyte and neutrophil
ounts; MDRD estimated glomerular ﬁltration rate (eGFR);
nd plasma concentrations of uric acid, calcium, phosphorus,
icarbonate, PTH, alkaline phosphatase, serum albumin and
-reactive protein. All the clinical biochemistry parameters
ere determined using conventional laboratory methods.
Previous history of gouty arthritis and the use of drugs
f interest for their potential relationship with CMP, such
s statins, allopurinol and erythropoiesis stimulating agents
ESA), were also included.
In a subgroup of 671 unselected patients, serum creatine
inase (CK) was determined to study the association between
habdomyolysis and CMP  or cramps.
In another subgroup of 361 unselected patients, serum
evels of 25-hydroxy-cholecalciferol were determined for com-
arison between patients with and without CMP.
tudy  design  and  statistical  analysis
n this cross-sectional study, we  describe the prevalence of
MP,  association with other symptoms, clinical and biochem-
cal characteristics of patients who  suffer from CMP,  and the
ost signiﬁcant differences compared to the rest of the study
roup. In addition, to establish whether CMP is predictive
f patient outcome, a univariate comparison was made of(4):433–440 435
survival of patients with and without CMP, adjusted for age
and gender.
Descriptive statistics are presented as mean and standard
deviation or as median and interquartile ranges (IQ) for con-
tinuous variables and as percentages for categorical variables.
For comparison of continuous variables, parametric tests
(Student’s t-test) or non-parametric tests (Mann–Whitney)
were used, depending on the type of distribution, while the
chi-square test was used for categorical variables.
To establish the independent association of the study
variables with CMP in the study group, multivariate logistic
regression was used. A ﬁrst analysis was performed to deter-
mine the symptoms best associated with CMP.  The following
independent variables were included in another separate
model: age; gender; comorbidity index; diabetes mellitus; body
mass index; leucocytes; neutrophils; uric acid; calcium; phos-
phorus; bicarbonate; PTH: C-reactive protein; and treatment
with statins, allopurinol or EPO. Automated stepwise regres-
sion was used for the selection of variables with the best
predictive models.
To analyse the differences in survival, Kaplan–Meier curves
(univariate analysis) and a Cox multivariate proportional haz-
ard model were used to adjust for differences in survival with
age and gender only (a more  exhaustive adjustment was not
justiﬁed).
A p < 0.05 was considered as statistically signiﬁcant, and all
the p values shown are bilateral. Statistical analyses were per-
formed with the IBM-SPSS 21.0 program (IBM Corp. Armonk,
USA).
Results
Prevalence  of  chronic  musculoskeletal  pain  and  associated
symptoms
The demographic, clinical and clinical biochemistry charac-
teristics of the 1169 patients included in the study are shown
in Table 1.
Of the patients studied, 441 (38%) had CMP.  CMP  was more
common among females than males (49% vs 28%; p < 0.0001).
The majority of the patients used paracetamol or metami-
zole for analgesia. At the time of their ﬁrst consultation, over
20% of the patients with CMP were also assiduously taking
nonsteroidal anti-inﬂammatory drugs. Less than 15% were
mixing paracetamol with tramadol or codeine. Less than 5%
of the patients with CMP were being treated with opioids
(fentanyl or other similar drugs) or pain-perception modi-
ﬁers (gabapentin or pregabalin); the signiﬁcant adverse effects
suffered by the patients treated with these drugs are worth
mentioning.
The prevalence of other symptoms is shown in Fig. 1
according to gender. The majority of the symptoms were more
prevalent among females than males. Apart from CMP,  other
symptoms that were notable due to their high prevalence were
fatigue, poor physical activity level, cold intolerance and pru-
ritus.
The prevalence of other symptoms is shown in Fig. 2
according to age quartile. There was a marked increase in
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Table 1 – Patient characteristics for the whole group and the subgroups with or without chronic musculoskeletal pain.
Total No pain Pain p
No. of patients 1169 728 (62%) 441 (38%)
Age (years) 65  (15) 62 (16) 70 (12) <0.000
Gender (% male) 54  63 41 <0.000
Comorbidity index: none; mild/moderate; severe (%) 32/52/16 37/49/14 24/56/20 <0.000
Diabetes mellitus (%) 37 34 41 0.012
BMI (kg/m2) 29.3 (5.8) 28.4 (5.4) 30.8 (6.1) <0.000
Haemoglobin (g/dl) 11.5 (3.9) 11.6 (4.7) 11.3 (1.6) 0.132
Total leucocytes (mm3) 8048 (2.63) 7925 (2.64) 8250 (2.62) 0.041
Neutrophils (mm3) 5411 (2.20) 5381 (2.30) 5459 (2.03) 0.556
eGFR, ml/min/1.73 m2 14.4 (4.9) 14.4 (4.9) 14.5 (5.0) 0.630
Uric acid (mg/dl) 7.6 (1.9) 7.7 (1.9) 7.4 (1.9) 0.035
Total calcium (mg/dl) 9.13 (0.79) 9.11 (0.83) 9.18 (0.74) 0.139
Phosphorus (mg/dl) 4.73 (1.11) 4.77 (1.18) 4.67 (0.99) 0.130
Bicarbonate (mmol/l) 21.6 (4.0) 21.4 (4.2) 21.7 (3.6) 0.252
PTH (pg/ml) 260 (219) 265 (222) 252 (214) 0.307
PTH < 100 pg/ml (%) 22 21 22 0.820
PTH > 500 pg/ml (%) 11 12 10 0.369
Alkaline phosphatase (IU/ml) 105 (59) 102 (56) 108 (63) 0.090
Serum albumin (g/dl) 3.87 (0.54) 3.88 (0.57) 3.86 (0.49) 0.456
C-reactive proteina (mg/l) 3.85 [13–11.04] 3.52 [1.27–9.35] 4.45 [1.72–13.31] 0.001
C-reactive protein >5 mg/l (%) 43 39 48 0.003
History of gouty arthritis, (%) 10 10 10 0.898
Statins (%) 53 52 54 0.357
Allopurinol (%) 23 22 25 0.281
ESA-EPO (%) 62 62 61 0.688
In order to investigate whether or not rhabdomyolysis coulda Median and IQ range.
CMP  and other symptoms like fatigue and decreased physical
exercise in the top 2 age quartiles (aged > 69).
By logistic regression, the symptoms most often associated
with CMP  were (Table 2) fatigue, pruritus, cramps, ecchymosis,
insomnia, oedema and dyspnoea.
Cold intolerance
Fatigue
Decrease in physical exercise
Cramps
Pain
Pruritus
Ecchymosis
Oedema
Night-time insomnia
Anorexia
Dyspnoea
Daytime drowsiness
Restless legs
Nausea-vomiting
Myoclonus
120 24 36 48 60
% patients
Males Females Total
Fig. 1 – Bar chart showing the prevalence of uraemic
symptoms in all patients studied and according to gender.Rhabdomyolysis  and  chronic  musculoskeletal  paincause or contribute to CMP, we included the CK plasma
Decrease in physical
exercise
Fatigue
Ecchymosis
Pain
Cold intolerance
Pruritus
Cramps
Oedema
Night-time insomnia
Anorexia
Daytime drowsiness
Dyspnoea
Nausea-vomiting
Restless legs
Myoclonus
120 24 36 48 60
% patients
1st  Quartile (<57) 2nd Quartile (57–69)
3rd  Quartile (69–77) 4th Quartile ( >77)
Fig. 2 – Bar chart showing the prevalence of uraemic
symptoms in patients grouped by age quartiles.
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Table 2 – Multivariate logistic regression. Uraemic symptoms most associated with the chronic musculoskeletal pain.
Variable Odds ratio 95% CI OR p
Fatigue (muscle weakness) 2.91 2.22–3.81 <0.000
Pruritus 1.75 1.34–2.28  <0.000
Cramps 1.62 1.24–2.11 <0.000
Oedema 1.59 1.19–2.11 0.001
Ecchymosis 1.55 1.18–2.03 0.002
Night-time insomnia 1.38 1.04–1.84 0.027
Dyspnoea 1.41 1.01–1.97 0.049
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Fig. 3 shows the survival curves for the patients who
had CMP as an initial symptom and those who  did not.
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Log range =9.34
P=.002
108 12 14The following did not ﬁt into the best model: anorexia; nausea/vomit
daytime drowsiness.
oncentrations from analyses of 671 non-selected patients (CK
tarted to be measured in all patients from 2006 onwards).
No signiﬁcant differences were found between patients
ith or without CMP  in mean CK concentration accord-
ng to gender (males with or without CMP: 124 ± 120 vs
40 ± 169 U/ml; females with or without CMP: 91 ± 59 vs
4 ± 79 U/ml).
Nor was there a higher rate of CK above normal limits
>194 U/ml) in patients with CMP  versus those without CMP
9.7 vs 14.4%).
We did ﬁnd a higher mean plasma concentration of CK in
en  who  had cramp compared to those not suffering from
ramp (161 ± 163 vs 120 ± 149 U/ml; p = 0.012). In women with
ramp, CK levels were also higher, although compared to
omen without cramp, the difference was only bordering on
tatistical signiﬁcance (101 ± 72 vs. 86 ± 67 U/ml; p = 0.058).
CK elevation above normal was more  common in all
atients (male and female) with cramp than those who did
ot suffer from cramp (17.4% vs 9.3%; p = 0.002).
In 391 patients treated with statins and in whom CK was
etermined, CK levels were signiﬁcantly higher than in the
80 patients not taking statins (133 ± 135 vs 94 ± 111 U/ml;
 < 0.0001). Also, a CK concentration above the normal limit
as more  common among patients on statins than among
hose not on statins (17 vs 6%; p < 0.0001).
erum  levels  of  25-hydroxycholecalciferol  and  chronic
usculoskeletal  pain
o signiﬁcant differences were found in 25-
ydroxycholecalciferol levels determined in 203 patients
ithout CMP  and 158 patients with CMP: 14.9 ± 8.4 vs
3.4 ± 8.5 ng/ml; p = 0.08.
Nor were signiﬁcant differences found between those with
r without CMP  in the percentage of patients with serum
5-hydroxycholecalciferol levels below 20 ng/ml (82 vs 77%;
 = 0.317).
etermining  factors  in  chronic  musculoskeletal  pain
able 1 shows the demographic, clinical and clinical biochem-
stry characteristics of the patients with or without CMP.
CMP  was most common in older women with comorbidity.
n addition to diabetes mellitus, other conditions signiﬁcantly
ssociated with CMP  were heart failure (100% of the patients
ith heart failure had CMP) and COPD (46% had CMP). In con-
rast, other comorbidities, such as coronary heart disease, CVAoor physical activity level; cold intolerance; myoclonus; restless legs;
or peripheral ischaemia, or a history of gouty arthritis were not
associated with higher rates of CMP.
Patients with CMP were more  obese, had higher C-reactive
protein and total leucocyte levels than the other patients, but
no differences were found in clinical biochemistry parameters
that characterise metabolic bone disease.
No differences were found in the prescribing of statins,
allopurinol or EPO.
By multivariate logistic regression, the best predictive
model for CMP (Table 3) had the following characteristics:
female; elderly; obese; comorbidity; and elevated inﬂam-
matory markers (C-reactive protein and non-neutrophil
leucocytes).
Chronic  musculoskeletal  pain  and  survival
We  followed up the progress of 1078 patients, collecting data
on death from any cause and date with censoring for end of
follow-up (February 2014), loss to follow-up or kidney trans-
plantation.
The median follow-up time was 1075 days (IQ ranges:
456–1756 days). During this period, 489 patients died (42% ofFig. 3 – Survival curves (Kaplan–Meier) in patients who
reported chronic musculoskeletal pain (red line, below) and
patients with no pain (blue line, above).
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Table 3 – Multivariate logistic regression. Clinical and analytical characteristics best associated with the chronic
musculoskeletal pain.
Variable Odds ratio 95% CI OR p
Male gender 0.458 0.350–0.600 <0.000
Age (×10 years) 1.31 1.20–1.42 <0.000
Comorbidity index
0 = none,
1 = mild/moderate,
2 = severe
1.282  1.038–1.584 0.021
BMI (×10 kg/m2) 1.55 1.31–1.79 0.000
Leucocytes (×1000/mm3) 1.303 1.136–1.494 <0.000
Neutrophils (×1000/mm3) 0.733 0.620–0.865 <0.000
C-reactive protein (×10 mg/l) 1.09 1.01–1.16 0.028
The following did not ﬁt into the best prediction model: uric acid; bicarbonate; albumin; PTH; alkaline phosphatase; diabetes; statins; ESA-EPO;
allopurinol; and glomerular ﬁltration rate.
Although the difference proved to be signiﬁcant in the univari-
ate comparison, when just age and gender were included in
a Cox proportional hazard regression model, the association
between CMP  and mortality was no longer signiﬁcant (Wald
0.193; p = 0.661).
Discussion
This study shows CMP to be a highly prevalent symptom
in patients with CKD, which is more  common in older,
obese women with comorbidity, especially diabetes, heart fail-
ure and COPD, and associated with inﬂammatory markers.
Patients with CMP  were also more  likely to have fatigue, pru-
ritus, cramps, insomnia, oedema and dyspnoea. In contrast,
CMP  did not appear to be associated with alterations in bone
and mineral metabolism, or signiﬁcant differences in plasma
levels of vitamin D, rhabdomyolysis, use of drugs (statins, EPO)
or gouty arthritis.
It is estimated that 10–20% of the general adult pop-
ulation suffers from some form of chronic pain.11–13 It is
reported to be more  common among older women, with
the prevalence heavily inﬂuenced by physical factors (obe-
sity, comorbidity), emotional factors (separation, divorce,
widowhood), psychological factors (anxiety, depression) and
social factors (education, employment and income).14 Around
50–70% of these pain syndromes are of musculoskeletal origin
(CMP), signifying that somewhere in the range of 5–14% of the
general population is affected by CMP.11–14 In fact, one study
in Spain states that over 20% of the general population suffers
from CMP.15
Despite the already high prevalence in the general popu-
lation, the ﬁgures observed in our population with CKD were
much higher still, making it extremely unlikely that this ﬁnd-
ing could be attributable to a variation within normal limits.
It has been reported that CMP  is very prevalent in patients
on dialysis,1,3,4 but also in CKD in predialysis stages,2,5,16 and
even in kidney transplant patients.10
As with the general population,17,18 in this study, we also
found a higher prevalence of CMP  among women  than among
men. The reason for CMP being more  likely to occur in females
is not fully understood. Apart from the fact that women tend
to be much more  explicit than men  when giving their medicalhistory (subjective assessment of the authors), which might
also explain the higher prevalence of other symptoms in the
women compared to the men  in our study population, there
is a hypothesis that females have greater sensitivity to pain
through mechanisms that may be related to both peripheral
and central perception systems.18
In this study, we ruled out CMP  being associated with rhab-
domyolysis, a disease that was diagnosed from serum CK
levels. However, we did ﬁnd abnormally high CK levels in
patients treated with statins and in those who  reported fre-
quent cramps.
Administration of EPO has been found to cause ﬂu-like ill-
ness with increased sensitivity to pain.19 In this study, we  did
not ﬁnd a higher rate of treatment with ESA-EPO in patients
with CMP.
In a study conducted in Asian patients with CKD, hyperuri-
caemia and gouty arthritis were found to be associated with
an increased incidence of CMP.5 In our study, we  observed no
signiﬁcant associations between CMP and uric acid concen-
trations in blood, treatment with xanthine-oxidase inhibitors,
or history of gouty arthritis.
An association has been reported between reduced levels
of blood vitamin D (25-hydroxycholecalciferol) and CMP  in the
general population.20 Low serum levels of vitamin D are very
common in CKD and, although the patients with CMP  in our
study had lower levels, the difference with respect to those
without CMP was not statistically signiﬁcant.
The prevalence of CMP increased in patients with comor-
bidity; particularly marked was that associated with heart
failure (100% of the cases). This ﬁnding also helps explain the
association found between CMP and both oedema and dys-
pnoea. Diabetes mellitus and COPD are also associated with
CMP. This increased prevalence of pain has previously been
reported in the literature in COPD patients21
One surprising ﬁnding in this study was the lack of associa-
tion between bone-mineral biochemical alterations and CMP.
Other studies have found a relationship between CMP  and ady-
namic bone disease,22 and also with high-remodelling bone
disease6,7,22; the latter of the two also being characterised by
the fact that the pain tends to be more  intense.
In this study, CMP was associated with poorer survival com-
pared to those who did not have CMP. The association between
CMP and mortality rates in CKD has also been demonstrated in
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nother study.23 However, when we  adjusted the proportional
azard model simply with gender and age in our patients, the
tatistical signiﬁcance of CMP  on the prediction of survival was
ancelled out.
As occurs in the general population,24 the CMP in our
atients was associated with higher levels of inﬂammatory
arkers, and this ﬁnding could help us to understand the
ossible mechanisms underlying the development of pain in
KD.25–27
Chronic inﬂammatory states are capable of sensitising
eripheral nociceptors (pain receptors) due to the numer-
us inﬂammatory mediator substances (interleukins, TNF,
rostaglandins, etc.).27 The sensitisation of nociceptors can
ometimes be so intense that they can end up being activated
pontaneously without the mediation of any injury.27
These same inﬂammatory mediators, and perhaps certain
raemic toxins, may also play an important role in the sen-
itisation of pain perception in the central nervous system
nd the balance of endogenous pain inhibitors (endorphins,
ndocannabinoids, GABA, etc.).25–27
This study has certain limitations. It is a cross-sectional
tudy, in which we  did not estimate the pain intensity, and
or did we  assess or describe the severity of musculoskele-
al damage and its relationship with the prevalence of CMP.
oreover, we  did not collect information on the patients’
ental health status or on their social/economic/cultural cir-
umstances, and that could affect the interpretation of the
esults.
In conclusion, CMP  is highly prevalent in patients with
dvanced CKD and is associated with other symptoms com-
on  in chronic uraemia. The main characteristics of the
atient with CMP  are: older female; obesity; certain comor-
idities; and elevated inﬂammatory markers.
Further studies are needed to analyse what type of anal-
esics or what additional supportive measures could be more
ffective and less toxic in this population.
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